Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • Platform
    • Strategy
    • Progress
    • Publications
  • Pipeline
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Mar 29, 2021 4:30pm EDT

Sonnet BioTherapeutics Provides 2021 Business Update

Mar 22, 2021 7:00am EDT

Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

Feb 16, 2021 8:10am EST

Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update

Feb 03, 2021 6:30am EST

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting

Feb 01, 2021 6:30am EST

Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates

Jan 25, 2021 6:30am EST

Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080

Dec 17, 2020 6:30am EST

Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update

Nov 30, 2020 8:30am EST

Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010

Sep 01, 2020 8:30am EDT

Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB)

Aug 25, 2020 7:30am EDT

Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants

RSS
  • 1
  • 2
  • 3
Next
© 2021 Sonnet BioTherapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap